Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates to chronic HF (CHF), particularly HF with reduced ejection fraction (HFrEF); significant unmet need remains in the treatment of HF with preserved ejection fraction (HFpEF). Additionally, the treatment of acute HF (AHF) is dominated by old, generic products. This report provides insights into the current and future CHF and AHF therapy markets, the performance of current market leader, Entresto, and the expected dynamics of the HFrEF and HFpEF therapy markets following the entries of several new therapies (Boehringer Ingelheim / Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Bayer / Merck Sharp & Dohme’s vericiguat, Cytokinetics’ omecamtiv mecarbil, and Bayer’s finerenone). This report also assesses how the AHF market will evolve given the lack of new drug launches in this patient population.
QUESTIONS ANSWERED
GEOGRAPHIES
United States, EU5, Japan.
PRIMARY RESEARCH
20 country-specific interviews with thought-leading cardiologists; supported by survey data collected for this and other Clarivate research.
EPIDEMIOLOGY
Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction.
FORECAST
10-year, annualized, drug-level sales and patient shares of key HF therapies through 2029, segmented by brands / generics and ejection fraction (HFrEF and HFpEF).
EMERGING THERAPIES
Phase III/PR: 7 drugs; Phase II: 10 drugs.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold